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Celalettin Ustun,1 Jirı Slaby,1 Ryan M. Shanley,2 Jan Vydra,1
Angela R. Smith,3 John E. Wagner,3 Daniel J. Weisdorf,1 Jo-Anne H. Young4Human parainfluenza viruses (HPIVs) are uncommon, yet high-risk pathogens after hematopoietic stem cell
transplant (HCT). We evaluated 5178 pediatric and adult patients undergoing HCT between 1974 and 2010
to determine the incidence, risk factors, response to treatment, and outcome of HPIV infection as well as any
change in frequency or character of HPIV infection over time. HPIV was identified in 173 patients (3.3%); type
3 was most common (66%). HPIV involved upper respiratory tract infection (URTI; 57%), lower respiratory
tract infection (LRTI; 9%), and both areas of the respiratory tract (34%), at a median of 62 days after trans-
plantation. In more recent years, HPIV has occurred later after HCT, whereas the proportion with nosoco-
mial infection and mortality decreased. Over the last decade, HPIV was more common in older patients and
in those receiving reduced intensity conditioning (RIC). RIC was a significant risk factor for later (beyond day
130). HPIV infections, and this association was strongest in patients with URTI. HCTusing a matched unre-
lated donor (MURD), mismatched related donor (MMRD), age 10 to 19 years, and graft-versus-host disease
(GVHD) were all risk factors for HPIV infections. LRTI, early (\30 days), age 10 to 19 years, MMRD, steroid
use, and coinfection with other pathogens were risk factors for mortality. The survival of patients with LRTI,
especially very early infections, was poor regardless of ribavirin treatment. HPIV incidence remains low, but
may have delayed onset associated with RIC regimens and improving survival. Effective prophylaxis and treat-
ment for HPIV are needed.
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6/j.bbmt.2012.04.012into 4 different types due to their genetic and antigenic
characteristics, although most clinical infections are
due to types 1, 2, and 3. HPIV can cause both upper
and lower respiratory tract infections (URTIs and
LRTIs), and less frequently, central nervous system in-
fections [1-3]. Clinical manifestations range widely,
from croup, otitis media, and bronchitis to life-
threatening pneumonitis [4-6]. The vast majority of
HPIV infections occur in infants and children [2]. A
second population vulnerable to HPIV infections is
immunocompromised patients including hematopoi-
etic stem cell transplant (HCT) recipients [1,7-14].
The incidence of HPIV has been reported between
2% to 7% after HCT [1,9,13]. Beyond this variation
in HPIV incidence after HCT, the preferred
treatment and impact on mortality are uncertain
[9,13,15,16].
We evaluated HPIV incidence, risk factors, out-
come, and response to treatment in pediatric and adult
patients undergoing autologous or allogeneic HCT
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sota.We evaluated changes in the timing and character
of HPIV infection over several decades, comparing the
frequency of HPIV infection, type of HPIV, clusters or
isolated infections, nosocomial or community-acquired
infections, URTIs or lower LRTIs, and seasonal
predominance.PATIENTS AND METHODS
Patient Population
This retrospective cohort study included 5178 con-
secutive pediatric and adult patients who receivedHCT
at the University of Minnesota (median age, 29; range,
0-74 years) between January 1974 and December
2010. Transplantation types included 1717 autoHCT
(33%) and 3461 alloHCT (67%). One hundred
seventy-three HPIV cases were identified, including 7
diagnosed in the2weeks beforeHCT.Patients received
conditioning for transplantation, prophylaxis of graft-
versus-host disease (GVHD) and infections per active
institutional protocols, which varied over the period
of study [17-19]. The intensity of conditioning
regimens was defined according to the Center for
International Blood and Marrow Transplant Research
(CIBMTR) guidelines [20]. For analysis, ex vivo and
in vivo (eg, antithymocyte globulin) T cell depletion
were combined as T cell depletion. All transplantation
protocols were approved by the University of Minne-
sota Institutional Review Board. All patients or their le-
gal guardians providedwritten informed consent for the
transplantation procedure including collection of long-
term prospective outcome data. The median follow-up
time for all survivors and for patientswithHPIVwas 6.5
and 6.0 years, respectively.
For patients demonstrating acute onset of URTI
symptoms, respiratory virus cultures of throat and/or
nasopharyngeal swabs or washes were obtained. For
any patient withHCT undergoing bronchoalveolar la-
vage (BAL), lung biopsy, or autopsy, respiratory virus
cultures were part of preplanned diagnostic protocols
and obtained on all samples.
Hospital in-patients with HPIV infection were
placed in droplet precautions, which involved using
gown, glove, and mask procedures to prevent spread
of infection to other patients or healthcare workers.
To evaluate any changing characteristics of HPIV
over time, we examined patients in 3 time periods:
1974 to 1992, 1993 to 2001, and 2002 to 2010. The first
periodwas composed of almost 2 decades because it had
fewer patients and it reflected the data from an early
transplantation era. Available data on 387 adult patients
surviving greater than 80 days were also evaluated for
late-onset noninfectious pulmonary complications
(LONIPCs) between 2002 and 2007. Diffuse alveolar
hemorrhage, idiopathic pneumonia syndrome, bron-chiolitis obliterans, and bronchiolitis obliterans with
organizing pneumonia were considered as LONIPCs.
Virology Procedures
Standard methods were used for isolation of HPIV
from respiratory samples. HPIV was isolated in tube
cultures containing a monolayer of primary rhesus-
monkey kidney cells and detected by hemadsorption
with guinea pig red cells at 3, 7, and 10 days. All
negative viral cultures were finalized at 21 days of incu-
bation. All BAL and lung tissue specimens were
concurrently submitted for bacterial, mycobacterial,
and fungal cultures. Sputum and autopsy samples
were submitted for bacterial and fungal cultures.
Isolates recovered in culture were typed by immu-
nofluorescence with commercially available antise-
rum. HPIV virus identification typically took 7 to 10
days overall: 7 days for types 1 and 3, and 8 to 9 days
for type 2.
Since January of 2004, the method of conventional
tube culturewas supplementedwith anR-Mix shell vial
culture (Diagnostic Hybrids, Athens, Ohio). Mono-
layer stainingwas checked at 2 days using a pooled stain
to detect parainfluenza viruses 1, 2, and 3, in addition to
other respiratory viruses.
Definitions
‘‘Infection episode’’ was defined as the cultured
presence of HPIV in a sample from the pulmonary
tree of a patient concomitantly displaying symptoms
compatible with clinical infection. Patients with symp-
toms/signs of croup, nasopharyngitis, conjunctivitis,
and otitis media were defined as URTI. URTI ex-
cluded dyspnea and/or newly appearing infiltrates on
radiographic imaging methods (chest radiograph or
computed tomography scan). Patients were considered
to have LRTI if they had symptoms/signs (eg, fever,
expiratory wheezing, tachypnea, dyspnea, retractions,
rales, or pulmonary infiltrates on chest X-ray or
computed tomography) of tracheobronchitis or pneu-
monia. Respiratory failure is defined as mechanical
ventilation occurring within 30 days of HPIV.
‘‘Nosocomial infection’’ was defined as infection
developing 5 or more days after hospital admission.
All other infections were classified as community
acquired.
‘‘Cluster infection’’ was defined as 3 or more cases
of nosocomial or community-acquired infection ap-
parent within a 30-day period.
‘‘Coinfection’’ was a second respiratory pathogen
occurring within a month of HPIV infection. Fever
of unknown origin was not categorized as coinfection.
Treatment of HPIV Infection
Treatment of HPIV infections depended on the
patient’s condition, URTI or LRTI, and was at the
1582 Biol Blood Marrow Transplant 18:1580-1588, 2012C. Ustun et al.discretion of treating physician. Those patients who
required treatment received aerosolized ribavirin.
Aerosolized ribavirin was administered as nebulization
through a mask or endotracheal tube. From 1984 to
1995, the drug was generally administered as 6 grams
in a continuous aerosol nebulization for 18 to 24 hours
per day. From 1995 to 2005, some patients received
aerosolized ribavirin using a schedule of 2 grams
over 2 hours 3 times daily. The duration of therapy dif-
fered between patients. Usually, a 5-day course of
treatment was delivered, unless continued symptoms
and/or ongoing positive cultures indicated a clinical
need for repeated or longer courses. Some patients re-
ceived i.v. immune globulin (Ig) along with ribavirin.
Data and Statistical Analysis
Analysis of the University of Minnesota Blood and
Marrow Transplant database was used for data extrac-
tion. TheUniversity of Minnesota HCT database con-
tains prospectively collected data on all patients who
underwent transplantation at our center. Clinical data
in this computerized research database included details
of antiviral medications used to treat HPIV infection
episodes. Additional clinical information was collected
from available medical records. For patients who never
developed HPIV, their first transplantation was in-
cluded for analysis. For patients with HPIV, the most
recent transplantation relative toHPIV onset was used.
Patient characteristics were compared by the chi-
square test. Cox regressionwas used to identify risk fac-
tors for HPIV, with time 0 set as the transplantation
date and time to HPIV as the outcome. A Fine and
Gray competing risks model was also fit to identify
risk factors forHPIV, accounting for death as a compet-
ing risk. These results (not reported) showed good
agreement with the Cox model. Cox regression was
used to identify risk factors for mortality within 100
days of HPIV and for subgroups with LRTI. Survival
time was taken as time from infection. No violations
of proportional hazards were detected. Multivariate
Cox models used a forward stepwise selection process
with a P value cutoff of .15 for inclusion in the final
model. Acute and chronic GVHD (aGVHD and
cGVHD) were considered as time-dependent covari-
ates. Additionally, the association between HPIV and
mortality was tested using a Cox model, with URTI
and LRTI as time-dependent covariates and adjusting
for other factors (diagnosis category, donor type, trans-
plant year, age, conditioning intensity, and cytomegalo-
virus [CMV]) potentially associated with survival.RESULTS
HPIV Patient and Infection Characteristics
Transplantation characteristics for patients with
HPIV infection and controls with no infection areshown in Table 1. HPIV infection was diagnosed in
173 patients (3.3%). The majority of HPIV infections
were caused by HPIV type 3 (66%; Figure 1). The
observed rates of nosocomial (41%) or community-
acquired (59%) infection and of cluster (45%) or sin-
gle case (55%) infection were similar. The median
interval from transplantation to HPIV infection was
62 days (range 28 to 1259 days). Most infections
(83%) occurred during the first year after transplanta-
tion, and more than one-half of infections (58%)
were diagnosed in the first 100 days; 34% in the first
30 days. HPIV infection affected only the upper re-
spiratory tract in 98 patients (57%), only lower respi-
ratory tract in 15 patients (9%), and both in 60
patients (34%). Among the 75 patients with LRTI,
43 (57%) were culture-positive in BAL; the rest of
the patients were diagnosed via radiologic or physical
examination findings supported by virologic dia-
gnostic material from noninvasive (nasal or throat)
sampling. Ribavirin with or without i.v. Ig was
administered to 51 patients (29%), 10 with URTI
(10%), and 41 with LRTI (55%).
Seasonal Prevalence of HPIV
HPIV infections occurred throughout the year
with similar rates, ranging from 40 to 53 events over
the 4 seasons (Figure 1). HPIV 3 was the most com-
mon isolate compared to other HPIV types through-
out the year and was more common in warmer
seasons (spring and summer, 76 events) compared
with autumn and winter (31 events; Figure 1).
Changes in HPIV over Time
Over time (1973-1992 versus 1993-2001 versus
2002-2010), the type of HPIV and total HPIV infec-
tion rate did not change (3.0% versus 3.2% versus
3.9%; P 5 .31; Figure 2). The proportion of nosoco-
mial HPIV infections (74% versus 30% versus 27%;
P\ .01) and early HPIV infections (diagnosed within
30 days post-HCT; 58% versus 24% versus 35%; P\
.01) decreased in the more recent eras. The median
time to HPIV infection was later as well occurring at
a median of 21 days (interquartile range [IQR], 6-79
days) from 1974 to 1992 compared with 135 days
(IQR, 45-395 days) from 1993 to 2001 and 75 days
(IQR, 18-210 days) from 2002 to 2010. The propor-
tion of cluster HPIV cases increased (29% versus
59% versus 50%; P \ .01; Figure 2), although this
may partly be due to more aggressive surveillance in
the latter eras.
A comparison of demographic data between the
patients with HPIV and the control group without
HPIV infection in different transplantation eras is
shown in Table 1. Over the last decade, HPIV
occurred more often in older patients and in patients
who received reduced-intensity conditioning (RIC;
Table 1. Comparison of Patients with HPIV with Patients with no HPIV over 3 Different Time Eras
Transplantation Era
1974-1992 1993-2001 2002-2010
Controls
n (%)
HPIV Cases
n (%)
P
Value
Controls
n (%)
HPIV Cases
n (%)
P
Value
Controls
n (%)
HPIV Cases
n (%)
P
Value
Number 1657 51 1737 57 1611 65
Median age 18.3 17.5 .85 32.8 33.1 .97 39.0 46.9 .14
Age by range .80 .10 .03
Age <10 514 (31) 18 (35) 424 (24) 14 (25) 346 (21) 8 (12)
Age 10-19 359 (22) 10 (20) 224 (13) 2 (4) 210 (13) 4 (6)
Age $20 784 (47) 23 (45) 1089 (63) 41 (72) 1055 (65) 53 (82)
Male 977 (59) 33 (65) .41 933 (54) 36 (63) .16 984 (61) 35 (54) .24
Donor sex match .57 .23 .60
Match 554 (51) 16 (46) 565 (52) 29 (60) 488 (43) 20 (39)
Mismatch 540 (49) 19 (54) 531 (48) 19 (40) 649 (57) 31 (61)
Diagnosis category .30 .39 .30
Lymphoid-malignant 227 (14) 4 (8) 306 (18) 12 (21) 401 (25) 18 (28)
Myeloid-malignant 1174 (71) 36 (71) 1127 (65) 32 (56) 886 (55) 39 (60)
Non-malignant 256 (15) 11 (22) 304 (18) 13 (23) 324 (20) 8 (12)
Autologous 563 (34) 16 (32) .70 641 (37) 9 (16) <.01 474 (29) 14 (22) .17
Allogeneic <.01 .76 .32
UCB 1 (<1) 0 (0) 140 (8) 7 (13) 590 (37) 26 (40)
Matched sibling 824 (50) 19 (37) 445 (26) 16 (28) 359 (22) 14 (22)
Other relatives 67 (4) 8 (16) 49 (3) 3 (5) 49 (3) 5 (8)
Unrelated 202 (12) 8 (16) 462 (27) 22 (39) 139 (9) 6 (9)
CMV serostatus .30 .84 .61
R+ 893 (54) 33 (65) 813 (47) 28 (49) 859 (53) 31 (48)
R2/D2 608 (37) 15 (30) 754 (43) 22 (39) 676 (42) 29 (45)
R2/D+ 115 (7) 2 (4) 165 (10) 5 (9) 69 (4) 4 (6)
Unknown 41 (3) 1 (2) 5 (<1) 2 (4) 7 (<1) 1 (2)
Conditioning intensity .20 .11 .01
Myeloablative + TBI 1266 (76) 35 (69) 1225 (71) 42 (74) 631 (39) 23 (35)
Myeloablative, no TBI 391 (24) 16 (31) 461 (27) 11 (19) 529 (33) 13 (20)
RIC 0 (0) 0 (0) 49 (3) 4 (7) 447 (28) 29 (45)
T depletion 433 (26) 20 (39) .04 288 (18) 19 (33) <.01 404 (25) 17 (26) .85
HPIV indicates human parainfluenza virus; UCB, umbilical cord blood; CMV, cytomegalovirus; R, recipient; D, donor; TBI, total body irradiation; RIC,
reduced-intensity conditioning.
P values represent chi-square comparisons of characteristics of HPIV infected versus control patients within each time era.
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conditioning regimen disparity in HPIV infection
rates was not apparent. In contrast, T cell depletion
was associated with more HPIV infections in earlier
decades; however, this difference was not noted
over the last decade. Sibling alloHCT was associated
with less HPIV in the earliest transplantation era
compared with the more recent decades of study.Figure 1. Frequency of human parainfluenza virus (HPIV) infections
per season.Coinfections
Coexisting infection with other pathogens was de-
tected in 68 patients with HPIV (39%). Organisms
identified concurrent with HPIV infections included
bacteria (55 patients), viruses (37 patients), and fungi
(19 patients, including 13 cases of Aspergillus). Polymi-
crobial infection occurred in 35 patients.
Association of HPIV with LONIPCs
Of 387 patients (22 with HPIV and 365 with no
HPIV), 65 developed LONIPCs. The rates of
LONIPCs were 23% and 17% in patients with
HPIV and no HPIV (P 5 .39), respectively.
Risk Factors for all-HPIV and LRT-HPIV
Infections
Multivariate analysis showed that mismatched
related donor (MMRD) and preceding cGVHD
were independent risk factors for both all-HPIV
and LRT-HPIV infections. The aGHVD and
a matched unrelated donor (MURD) were risk factors
for HPIV infection. RIC regimens were risk factors
Figure 2. Trends of infection characteristics over time.
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(Table 2). This effect was strongest in patients with
URTI (hazard ratio [HR], 3.0; 95% confidence
interval [CI], 1.4-6.1; P\ .01). Male recipients had
more frequent LRTI. Umbilical cord blood trans-
plants and MURDs showed a trend for increased
LRTIs.Respiratory Failure and Survival
The need for mechanical ventilation within 30
days of HPIV infections and of LRT-HPIV infections
was 19% and 43%, respectively. The 100-day survival
from the onset of mechanical ventilation was 23% in
these patients. By comparison, 100-day survival from
the onset of mechanical ventilation was similar in other
patients with uninfected HPIV (22%). In multivariate
analysis, LRTI (HR, 2.6; 95%CI, 1.3-5.4; P\ .01) but
not URTI was associated with increased mortality
(Figure 4A), and the mortality of patients with LRTI
at 100 days after infection decreased over time: 71%
(15 of 21 patients) from 1974 to 1992, 25% (6 of 24Figure 3. Incidence of human parainfluenza virupatients) from 1993 to 2001, and 37% (11 of 30
patients) from 2002 to 2010.
In multivariate analysis, LRTI, age 10 to 19 years
(HR, 4.2; 95% CI, 1.8-9.9; P\ .01), MMRD (HR,
3.8; 95% CI, 1.7-8.5; P\ .01), early HPIV infection
(HR, 2.3; 95% CI, 1.2-4.3; P\ .01; Figure 4B), the
presence of coinfection (HR, 2.1; 95% CI, 1.0-4.2;
P 5 .04), and steroid use (HR, 2.0; 95% CI, 1.0-
3.9; P 5 .05) were also found to be risk factors for
mortality. Transplantation era and nosocomial acqui-
sition of HPIV were not independent risk factors for
mortality as they were significant only in univariate
analysis.Anti-Viral Treatment and Outcome
Overall, treated patients with HPIV had higher
mortality rates at 100 days after infection compared
with those who were not treated (40% versus 15%;
P\ .01; Figure 4C), although clinical factors including
the acuity at presentation may, of course, have directly
influenced the decision to initiate specific therapy.s (HPIV) by year and conditioning intensity.
Table 2. Multivariate Analysis of Risk Factors for All and LRT-HPIV Infections
Factor
All HPIV LRTI
Risk ratio (95% CI) P Value Risk ratio (95% CI) P Value
Donor type
Autologous Ref Ref
UCB 1.4 (0.8-2.5) .31 2.4 (1.0-6.1) .06
Matched related 0.9 (0.6-1.6) .80 1.4 (0.6-3.2) .41
Matched unrelated 2.0 (1.1-3.7) .03 2.3 (0.8-6.0) .11
Mismatched related 3.2 (1.6-6.3) <.01 7.0 (2.7-18.3) <.01
Mismatched unrelated 1.3 (0.6-2.7) .55 0.9 (0.3-3.8) .98
Gender
Male Ref Ref
Female 0.9 (0.7-1.3) .75 0.6 (0.3-1.0) .04
Diagnosis category
Lymphoid/malignant 1.2 (0.8-1.8) .46 1.0 (0.5-1.9) .89
Myeloid/malignant Ref Ref
Non-malignant 1.1 (0.7-1.8) .66 0.9 (0.4-2.1) .89
CMV
R+ 1.0 (0.7-1.5) .80 1.5 (0.9-2.5) .15
R2/D2 Ref Ref
R2/D+ 0.9 (0.4-1.7) .66 1.2 (0.5-3.2) .66
Unknown 2.1 (0.6-6.9) .22 0.0 (0.0-0.0) .98
Age
Age <10 0.8 (0.5-1.3) .42 0.6 (0.3-1.3) .18
Age 10-19 0.5 (0.3-0.9) .03 0.5 (0.2-1.1) .07
Age $20 Ref Ref
Transplantation era
1974-1992 0.8 (0.5-1.4) .56 0.8 (0.4-1.6) .47
1993-2001 0.7 (0.3-1.8) .48 0.9 (0.5-1.7) .71
2002-2010 Ref Ref
RIC (risk <30 d) 0.7 (0.3-1.8) .48 0.5 (0.1-1.9) .54
RIC (risk $30 d) 2.1 (1.2-3.5) .01 1.4 (0.6-3.1) .42
aGVHD 1.9 (1.1-3.4) .03 2.1 (0.8-5.3) .11
cGVHD 6.2 (3.7-10.4) <.01 7.1 (3.4-14.8) <.01
LRT indicates lower respiratory tract; HPIV, human parainfluenza virus; LRTI, lower respiratory tract infection; CI, confidence interval; UCB, umbilical
cord blood; CMV, cytomegalovirus; R, recipient; D, donor; RIC, reduced-intensity conditioning; Ref, reference group for each comparison category;
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
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virin treatment led to similar mortality at 100 days
after infection (46%) as compared with no treatment
with ribavirin (38%; P 5 .60).DISCUSSION
This long-term study has shown, we believe for the
first time, how RIC has changed HPIV infections over
time. Over the 35 years of study, we observed a rela-
tively stable incidence (approximately 3%) ofHPIV in-
fection in our large HCT population, similar to that
shown by our and other earlier studies [1,9,13].
Notably, the age of patients with HPIV has increased
over the decades of study. HPIV 3 was the most
common type we observed, which is consistent with
data showing that HPIV 3 is the most common type
in healthy community-based pediatric populations
[1,2,9,13,21]. Most HPIV 3 cases were diagnosed in
warmer seasons among our patients with HCT,
which was also consistent with data showing that
spring is its peak season in the general population
[22]. Limitations of this retrospective cohort study
include changes in the duration of follow-up ofpatients over time, as patients in the latter years of the
study had only several years of long-term follow-up.
RIC regimens were found to be a risk factor for
HPIV infection occurring later than the first 30
days posttransplantation. Most of these patients had
URTIs. Although RIC was used mostly in older pa-
tients, older patients experienced similar HPIV com-
pared with younger patients, and higher incidents of
HPIV among patients with RIC were present in all
age groups. Moreover, although both aGVHD and
cGVHD increased HPIV infections, RIC remained
as a risk factor in the multivariate analysis. Recent
patients who underwent transplantation might be fol-
lowed longer at transplantation centers, live longer,
or HPIV might be considered more often within
time, which could have explained the increased
HPIV with RIC regimens. On the other hand, trans-
plantation era was not a significant factor for HPIV
infections in the multivariate analysis. Therefore,
RIC regimens seem to increase delayed HPIV
infections.
Despite stability in the incidence of HPIV, there
has been a change in the day of onset with more recent
HPIV infections occurring later post-HCT. This later
Figure 4. (A) Lower respiratory tract infection (LRTI) with human par-
ainfluenza virus (HPIV) is associated with higher mortality than upper re-
spiratory tract infection (URTI). (B) Higher mortality with early onset
(\30 days) of LRT-HPIV. (C) Effect of antiviral treatment for LRT-HPIV
on survival. Abbreviations: IVIG 5 intravenous immune globulin.
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comial infections, more cluster infections, and slightly
lower mortality. This delay may be due in part to
a change in screening practices, as well as ongoing
virologic surveillance at later time points after HCT.
Our recognition of late infections has increased, be-
cause patients remain under review at transplantation
centers longer, and patients survive longer, remaining
at risk to develop infection later after HCT. Other as
yet undefined changes in our clinical practice of
HCT may influence this epidemiology as well.
In recent years, testing for respiratory viruses has
come to include PCR testing, together with or in place
of culture or shell vial testing. Several studies have
shown that RT-PCR and real-time PCR with specificprimers and probes for each type of HPIV are more
sensitive and specific than both viral culture and
immunofluorescence-based detection methods [23-
27]. The use of nucleic acid detection is so new that
only future studies will be able to determine whether
the incidence will change once most centers start
exclusively using PCR testing. In the setting of
alloHCT, these methods have detected viruses even
in asymptomatic patients with negative cultures
[8,27]. Taking into account these asymptomatic
patients and low sensitivity of cultures, the current
incidence of HPIV may be underestimated.
Higher risks for developing HPIV infection were
observed with certain donor types (MUD and
MMRD), and in patients with aGVHD and cGVHD.
RIC was also a risk factor for later infection. RIC reg-
imens are reportedly associated with increased delayed
rate of viral infections, including CMV [28,29].
Chakrabarti et al. [21] reported that median time to
HPIV infection from RIC alloHCT was 72 days,
which is very similar to our finding (75 days) over the
last decade. Alemtuzumab-containing RIC regimens
were associated with increased HPIV infections, but
not with high mortality rates [21].
Risks for mortality after HPIV infection included
LRTI and early infections after HCT. Mortality
from LRTI has improved over decades. However, re-
spiratory failure requiring mechanical ventilation
remained a poor prognostic factor for survival, which
was similar to patients with uninfected HPIV in this
study. Mechanical ventilation need was a significant
risk factor for mortality in a report from Seattle as
well [9]. Early HPIV infection associated with higher
mortality was reported with 16% (10 of 61 patients)
mortality in patients with HPIV overall, which was
higher (21%) in patients with early (\100 days)
HPIV infection versus only 5% for later infections
[13]. We also observed higher mortality after
MURD and MMRDHCT, patients age 10 to 19, ste-
roid use, and the presence of coinfections. Concurrent
other infections have also been noted to increase risks
of mortality in other studies [9,13].
Ribavirin with or without i.v. Ig was administered
for some patients with HPIV, but with no demonstra-
ble improvement in survival, similar to some, but not
all earlier reports [9,30,31]. However, differences in
prognostic factors in those treated or not treated may
preclude definitive conclusions. There is clinical bias
in choosing who to treat with ribavirin, as they may
seem sicker. Moreover, because of the limited
number of treated patients with URTI, the efficacy
of ribavirin in patients with less-severe infections is
unknown. Sparrelid et al. [30] suggested that in pa-
tients with viral LRTIs, the level of nebulized ribavirin
might be limited by bronchospasm or tissue inflamma-
tion blocking delivery of an aerosolized drug to distal
parts of the lungs. This early study suggested that
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was associated with hemolysis [32].
Prophylaxis of HPIV infection may be more
important given that no effective antiviral therapy is
available. HPIV vaccines have been developed, but
are not licensed or used for routine clinical practice
[33,34]. The nonseasonal nature of HPIV differs
from respiratory syncytial virus, which is distinctly
seasonal and can be recognized as a threat during
community-associated outbreaks in children.
Moreover, asymptomatic HPIV infection and
shedding may occur in the HCT setting, making it
difficult to know who is contagious [8]. The low rate
of shedding also makes surveillance using PCR analy-
sis cost-prohibitive and thereby impairs the prevention
of HPIV infection by isolation for these contagious,
yet asymptomatic patients with HPIV. Aggressive
screening for respiratory viral infection during any
URTI symptoms (year-round) may be the most
valuable method to limit HPIV infections and their
associated morbidity and mortality after HCT. Once
an HPIV vaccine is commercially available, systematic
vaccination of donors, HCT staff, and close patient
contacts would be an additional prophylactic measure
to prevent HPIV infections.
This study shows that HPIV infection occurring
in later phases of alloHCT (RIC is a risk factor)
may be less serious than HPIV infections occurring
very early posttransplantation, which can increase
mortality. Treatment of HPIV in LRTIs has not im-
proved survival. Therefore, extreme caution should
be taken to prevent infection from infected individ-
uals to these hospitalized patients. Moreover, any pa-
tients with respiratory symptoms with imminent
transplantation should be tested for HPIV, and trans-
plantation should be postponed until the results are
negative for HPIV.ACKNOWLEDGMENTS
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